Literature DB >> 22231845

Development of Parkinson's disease in patients with Narcolepsy.

Chadwick W Christine1, William J Marks, Jill L Ostrem.   

Abstract

Although amphetamine drugs can damage dopaminergic axons, it is unknown whether chronic treatment with amphetamine increases the risk of developing Parkinson's disease (PD). Of 1,152 consecutive PD patients, 3 had a prior diagnosis of narcolepsy. This rate is five times higher than expected (p = 0.02). These patients had typical onset of narcolepsy and underwent treatment with amphetamine. Although preliminary, this observation raises the possibility that some factors intrinsic to narcolepsy or its treatment may be a risk factor for PD.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22231845     DOI: 10.1007/s00702-011-0761-z

Source DB:  PubMed          Journal:  J Neural Transm (Vienna)        ISSN: 0300-9564            Impact factor:   3.575


  11 in total

1.  Incidence of Parkinson's disease among hospital patients with methamphetamine-use disorders.

Authors:  Russell C Callaghan; James K Cunningham; Gautam Sajeev; Stephen J Kish
Journal:  Mov Disord       Date:  2010-10-30       Impact factor: 10.338

2.  Amphetamine exposure is elevated in Parkinson's disease.

Authors:  Elisabeth R Garwood; Wosen Bekele; Charles E McCulloch; Chadwick W Christine
Journal:  Neurotoxicology       Date:  2006-03-28       Impact factor: 4.294

Review 3.  Is methamphetamine abuse a risk factor in parkinsonism?

Authors:  T R Guilarte
Journal:  Neurotoxicology       Date:  2001-12       Impact factor: 4.294

4.  Amphetamine treatment similar to that used in the treatment of adult attention-deficit/hyperactivity disorder damages dopaminergic nerve endings in the striatum of adult nonhuman primates.

Authors:  George A Ricaurte; Annis O Mechan; Jie Yuan; George Hatzidimitriou; Tao Xie; Andrew H Mayne; Una D McCann
Journal:  J Pharmacol Exp Ther       Date:  2005-07-13       Impact factor: 4.030

5.  Excessive daytime sleepiness and subsequent development of Parkinson disease.

Authors:  R D Abbott; G W Ross; L R White; C M Tanner; K H Masaki; J S Nelson; J D Curb; H Petrovitch
Journal:  Neurology       Date:  2005-11-08       Impact factor: 9.910

Review 6.  Methamphetamine neurotoxicity: necrotic and apoptotic mechanisms and relevance to human abuse and treatment.

Authors:  C Davidson; A J Gow; T H Lee; E H Ellinwood
Journal:  Brain Res Brain Res Rev       Date:  2001-08

7.  Parkinson's disease comorbid with narcolepsy presenting low CSF hypocretin/orexin level.

Authors:  Tetsuya Maeda; Ken Nagata; Hideaki Kondo; Takashi Kanbayashi
Journal:  Sleep Med       Date:  2006-11-13       Impact factor: 3.492

8.  Striatal dopamine nerve terminal markers in human, chronic methamphetamine users.

Authors:  J M Wilson; K S Kalasinsky; A I Levey; C Bergeron; G Reiber; R M Anthony; G A Schmunk; K Shannak; J W Haycock; S J Kish
Journal:  Nat Med       Date:  1996-06       Impact factor: 53.440

9.  Prevalence of narcolepsy symptomatology and diagnosis in the European general population.

Authors:  M M Ohayon; R G Priest; J Zulley; S Smirne; T Paiva
Journal:  Neurology       Date:  2002-06-25       Impact factor: 9.910

10.  Reduced striatal dopamine transporter density in abstinent methamphetamine and methcathinone users: evidence from positron emission tomography studies with [11C]WIN-35,428.

Authors:  U D McCann; D F Wong; F Yokoi; V Villemagne; R F Dannals; G A Ricaurte
Journal:  J Neurosci       Date:  1998-10-15       Impact factor: 6.167

View more
  8 in total

1.  Ictal SPECT in patients with rapid eye movement sleep behaviour disorder.

Authors:  Geert Mayer; Marion Bitterlich; Torsten Kuwert; Philipp Ritt; Hermann Stefan
Journal:  Brain       Date:  2015-03-01       Impact factor: 13.501

Review 2.  Sleep disorders, obesity, and aging: the role of orexin.

Authors:  Joshua P Nixon; Vijayakumar Mavanji; Tammy A Butterick; Charles J Billington; Catherine M Kotz; Jennifer A Teske
Journal:  Ageing Res Rev       Date:  2014-11-22       Impact factor: 10.895

3.  Narcolepsy: clinical differences and association with other sleep disorders in different age groups.

Authors:  Sona Nevsimalova; Juraj Pisko; Jitka Buskova; David Kemlink; Iva Prihodova; Karel Sonka; Jelena Skibova
Journal:  J Neurol       Date:  2012-10-16       Impact factor: 4.849

4.  Comorbidity and mortality of narcolepsy: a controlled retro- and prospective national study.

Authors:  Poul Jennum; Rikke Ibsen; Stine Knudsen; Jakob Kjellberg
Journal:  Sleep       Date:  2013-06-01       Impact factor: 5.849

Review 5.  Sleep Attacks in Patients With Parkinson's Disease on Dopaminergic Medications: A Systematic Review.

Authors:  Eugene Y H Yeung; Andrea E Cavanna
Journal:  Mov Disord Clin Pract       Date:  2014-09-01

6.  Dysautonomia in narcolepsy: evidence by questionnaire assessment.

Authors:  Gilles Klein; Lothar Burghaus; Michel Vaillant; Vannina Pieri; Gereon R Fink; Nico Diederich
Journal:  J Clin Neurol       Date:  2014-10-06       Impact factor: 3.077

Review 7.  Dopamine compartmentalization, selective dopaminergic vulnerabilities in Parkinson's disease and therapeutic opportunities.

Authors:  George R Uhl
Journal:  Ann Clin Transl Neurol       Date:  2019-01-08       Impact factor: 4.511

8.  Cardiac Sympathetic Activity differentiates Idiopathic and Symptomatic Rapid Eye Movement Sleep Behaviour Disorder.

Authors:  Lucie Barateau; Isabelle Jaussent; Régis Lopez; Elisa Evangelista; Sofiene Chenini; Meriem Benkiran; Denis Mariano-Goulart; Yves Dauvilliers
Journal:  Sci Rep       Date:  2018-05-08       Impact factor: 4.379

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.